Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis.

MLA

Ramos-Molina, Bruno, et al. “Therapeutic Implications for Sphingolipid Metabolism in Metabolic Dysfunction-Associated Steatohepatitis.” Frontiers in Endocrinology, July 2024, pp. 01-17. EBSCOhost, https://doi.org/10.3389/fendo.2024.1400961.

APA

Ramos-Molina, B., Rossell, J., Pérez-Montes de Oca, A., Pardina, E., Genua, I., Rojo-López, M. I., Julián, M. T., Alonso, N., Julve, J., & Mauricio, D. (2024). Therapeutic implications for sphingolipid metabolism in metabolic dysfunction-associated steatohepatitis. Frontiers in Endocrinology, 01-17. https://doi.org/10.3389/fendo.2024.1400961

Chicago

Ramos-Molina, Bruno, Joana Rossell, Alejandra Pérez-Montes de Oca, Eva Pardina, Idoia Genua, Marina I. Rojo-López, María Teresa Julián, Núria Alonso, Josep Julve, and Didac Mauricio. 2024. “Therapeutic Implications for Sphingolipid Metabolism in Metabolic Dysfunction-Associated Steatohepatitis.” Frontiers in Endocrinology, July, 01-17. doi:10.3389/fendo.2024.1400961.